Provided by Tiger Fintech (Singapore) Pte. Ltd.

HENLIUS

31.700
-0.150-0.47%
Volume:2.48M
Turnover:82.71M
Market Cap:17.23B
PE:19.85
High:34.050
Open:31.850
Low:31.600
Close:31.850
Loading ...

Phase 3 Study for Henlius, Essex's Wet Age-Related Macular Degeneration Drug Reaches Primary Endpoint; Essex Shares Up 11%

MT Newswires Live
·
03 Apr

BRIEF-Shanghai Henlius Biotech Updates On Phase 3 Clinical Study Of HLX04-O

Reuters
·
02 Apr

Shanghai Henlius Biotech - Recombinant Anti-Vegf Humanised Monoclonal Antibody Injection Hlx04-O Phase 3 Clinical Study Met Primary Study Endpoint

THOMSON REUTERS
·
02 Apr

Organon, Henlius Say EMA Validates Marketing Authorization Application for Proposed Breast Cancer Drug

MT Newswires Live
·
28 Mar

BRIEF-Shanghai Henlius Biotech Updates On Pertuzumab Biosimilar HLX11

Reuters
·
28 Mar

Shanghai Henlius Biotech Inc - Marketing Authorization Application ( for Pertuzumab Biosimilar Hlx11 Validated by European Medicines Agency

THOMSON REUTERS
·
28 Mar

Shanghai Henlius Biotech Gets Approval for Kidney Treatment Clinical Trial in China; Shares Rise 3%

MT Newswires Live
·
26 Mar

BRIEF-Shanghai Henlius Biotech Updates On Phase 2 Clinical Trial Of HLX79 Injection

Reuters
·
25 Mar

Shanghai Henlius Biotech - Application for Phase 2 Clinical Trial of Hlx79 Injection in Combination With Hanlikang Approved by Nmpa

THOMSON REUTERS
·
25 Mar

Henlius 2024 Annual Results: Steady Revenue Growth With a Net Profit of RMB820.5 Million, up by 50.3% YoY

THOMSON REUTERS
·
24 Mar

Press Release: Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY

Dow Jones
·
24 Mar

BRIEF-Shanghai Henlius Biotech Says Wenjie Zhang Re-Designated From Executive Director

Reuters
·
24 Mar

BRIEF-Shanghai Henlius Biotech Posts FY Revenue RMB 5,724.4 Million

Reuters
·
24 Mar

Shanghai Henlius Biotech FY Operating Income RMB 5,724.4 Million

THOMSON REUTERS
·
24 Mar

Shanghai Henlius Biotech Inc - Wenjie Zhang Re-Designated From an Executive Director to a Non-Executive Director

THOMSON REUTERS
·
24 Mar

Alligator Bioscience Announces FDA Orphan Drug Designation For HLX22/AC101

Reuters
·
20 Mar

Shanghai Henlius Biotech Says Orphan-Drug Designation Granted By US FDA

Reuters
·
19 Mar

Shanghai Henlius Biotech - Orphan-Drug Designation of Hlx22 (Recombinant Humanized- Anti-Her2 Monoclonal Antibody Injection) Granted by US FDA

THOMSON REUTERS
·
19 Mar

BRIEF-UBS Group's Long Position In H Shares Of Shanghai Henlius Biotech Increases To 7.55% - HKEX

Reuters
·
19 Feb

UBS Group's Long Position in H Shares of Shanghai Henlius Biotech Increases to 7.55% on Feb 13 From 5.43% - HKEX

THOMSON REUTERS
·
19 Feb